Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.37 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4488636 | 0.80 | SLC22A6 (0.42) | SMN1; SMN2SLC22A6TDP1TP53MAPT | |
| SCHEMBL5077944 | 0.80 | SLC22A6 (0.50) | SMN1; SMN2SLC22A6TSHRTDP1MAPT | |
| SCHEMBL304303 | 0.80 | SLC22A6 (0.50) | SMN1; SMN2SLC22A6TSHRTDP1MAPT | |
| Cadaverine Tartrate SCHEMBL29124670 | 0.79 | TSHR (0.53) | SMN1; SMN2SLC22A6TSHRTDP1TP53 | |
| SCHEMBL2685811 | 0.78 | — | — | |
| SCHEMBL3575582 | 0.78 | — | — | |
| SCHEMBL28738599 | 0.78 | — | — | |
| SCHEMBL4854472 | 0.78 | — | — | |
| SCHEMBL11409855 | 0.78 | — | — | |
| SCHEMBL28738600 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119908965-A | Composition for reinforcing keratin fibres | 威娜德国有限责任公司 | 2025-05-02 | — | — | CN | claimed |
| CN-116370326-B | Composition for reinforcing keratin fibres | 威娜德国有限责任公司 | 2025-05-02 | — | — | CN | claimed |
| EP-4500182-A1 | PROGNOSTIC BIOMARKERS | The University of Liverpool (GB) | 2025-02-05 | — | — | EP | claimed |
| WO-2023180753-A1 | PROGNOSTIC BIOMARKERS | THE UNIVERSITY OF LIVERPOOL (GB) | 2023-09-28 | — | — | WO | claimed |
| CN-116370326-A | Composition for reinforcing keratin fibres | 威娜德国有限责任公司 | 2023-07-04 | — | — | CN | claimed |
| US-11412953-B2 | Diagnosis of asthma versus chronic obstructive pulmonary disease (COPD) using urine metabolomic analysis | UNIVERSITY OF SASKATCHEWAN (CA) | 2022-08-16 | — | — | US | claimed |
| CN-116370326-B | Composition for reinforcing keratin fibres | 威娜德国有限责任公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-119908965-A | Composition for reinforcing keratin fibres | 威娜德国有限责任公司 | 2025-05-02 | — | — | CN | disclosed |
| EP-4500182-A1 | PROGNOSTIC BIOMARKERS | The University of Liverpool (GB) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023180753-A1 | PROGNOSTIC BIOMARKERS | THE UNIVERSITY OF LIVERPOOL (GB) | 2023-09-28 | — | — | WO | disclosed |
| US-20230295195-A1 | ANTIMICROBIAL ORGANOSILANES | Tipikos Pharmaceuticals, Inc. (US) | 2023-09-21 | — | — | US | disclosed |
| CN-116370326-A | Composition for reinforcing keratin fibres | 威娜德国有限责任公司 | 2023-07-04 | — | — | CN | disclosed |
| US-20210139390-A1 | PRODUCTION METHOD OF ORGANIC COMPOUND | UNITIKA LTD. (JP) | 2021-05-13 | — | — | US | disclosed |
| US-9023636-B2 | Microorganisms and methods for the biosynthesis of propylene | GENOMATICA, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-8617862-B2 | Microorganisms for producing propylene and methods related thereto | GENOMATICA, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2563926-A1 | MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF PROPYLENE | Genomatica, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20120329119-A1 | MICROORGANISMS FOR PRODUCING PROPYLENE AND METHODS RELATED THERETO | GENOMATICA, INC. | 2012-12-27 | — | — | US | disclosed |
| WO-2011137198-A1 | MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF PROPYLENE | GENOMATICA, INC. (US) | 2011-11-03 | — | — | WO | disclosed |
| US-20110269204-A1 | MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF PROPYLENE | AGAIN BIO APS (DK) | 2011-11-03 | — | — | US | disclosed |
| CN-102038035-A | Method for preparing apple medlar yogurt | JING ZHAO | 2011-05-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295195-A1 | ANTIMICROBIAL ORGANOSILANES | ARG1, ACMSD, AAAS | SMN1; SMN2 3283/4885SLC22A6 1842/4885TSHR 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.